WONDERLAB and the First Affiliated Hospital of Sun Yat-sen University Launch a Clinical Study of S100 Probiotics for Weight Management

On February 22, WONDERLAB and the First Affiliated Hospital of Sun Yat-sen University (hereinafter “the First Affiliated Hospital”) officially launched in Guangzhou a clinical study of SHAPE100™ Probiotics (hereinafter “S100”) for weight management. Experts attending the launch included Hong Hua, Deputy Director of the Hospital Management Office of Sun Yat-sen University, Director of Special Medical Services and Director of the Health Management Center at the First Affiliated Hospital; Huilian Zhu, Vice President and Secretary-General of the Guangdong Nutrition Society and Professor at the School of Public Health, Sun Yat-sen University; Xiaoying He, Associate Chief Physician in the Department of Endocrinology at the First Affiliated Hospital; and Jing Mou, Director of Medical Affairs at WONDERLAB.

The launch event for the WONDERLAB SHAPE100™ Probiotics clinical study on weight management

According to World Health Organization (WHO) data, the global number of people with obesity has almost tripled since 1975 and now exceeds 650 million. In response to this situation, WONDERLAB officially launched S100 weight-management probiotics in January 2024 and quickly rose to the top positions in sales rankings across major e-commerce platforms. S100 combines WONDERLAB’s proprietary strain Lactobacillus acidophilus GOLDGUT-LA100 with three imported strains recognized under the European Food Safety Authority’s Qualified Presumption of Safety (QPS) framework and clinically studied for their potential to support metabolic health: Lactiplantibacillus plantarum CECT7527, CECT7528 and CECT7529. It is also formulated with multiple prebiotics and functional ingredients intended to support healthy weight.

At the launch event, Huilian Zhu, Vice President and Secretary-General of the Guangdong Nutrition Society and Professor at the School of Public Health, Sun Yat-sen University, said: “The global obesity rate continues to rise. Obesity affects quality of life and is closely associated with chronic conditions such as cardiovascular disease and type 2 diabetes. People with obesity face a 2–3 times higher risk of cardiovascular disease than people at a normal weight, while their risk of type 2 diabetes is as high as 5–10 times greater.”

Huilian Zhu, Vice President and Secretary-General of the Guangdong Nutrition Society and Professor at the School of Public Health, Sun Yat-sen University

According to the source, in 2024 the National Health Commission, together with 16 other departments, launched the “Weight Management Year” campaign and developed its implementation plan. WONDERLAB and the First Affiliated Hospital will focus this study on science-based weight management, combining S100 probiotics with a medical intervention agent for obesity. Through a series of rigorous clinical trials, the study will investigate the potential value of this combination and provide consumers with more science-based and health-oriented weight-management options.

Hong Hua gave a detailed introduction to the research direction for S100 probiotics. He said: “Although a range of weight-loss treatments are available, they still have limitations. As a multi-strain probiotic product, WONDERLAB’s S100 has been indicated in clinical research to support fat metabolism. Used in combination with the agent, S100 may help improve gastrointestinal responses and enhance weight-loss outcomes.”

Hong Hua, Deputy Director of the Hospital Management Office of Sun Yat-sen University, Director of Special Medical Services and Director of the Health Management Center at the First Affiliated Hospital

As a leading medical institution in China, the First Affiliated Hospital has substantial strengths in medical research and clinical practice. Its collaboration with WONDERLAB is a practical example of deeper industry–academia–research integration. The partnership will draw on both parties’ strengths in research and product development, while the S100 clinical study for weight management is expected to bring new advances to the field and help more people pursue healthy weight-management goals.